GW Pharma's (GWPH) Epidiolex Looks Strong Out of Gate, PT To $191 At Stifel

Stifel analyst, Paul Matteis, reiterated his Buy rating on shares of GW Pharma (NASDAQ: GWPH) and raised his price target to $191 from $179 after the company reported an impressive 4Q18 highlighted by Epidiolex revenues of $4.7MM, above consensus of $2.5MM.

The analyst stated "While expectations were already somewhat high, quantitative (4500 start forms in Nov/Dec) and qualitative feedback (very bullish on reimbursement) reaffirm our view that the launch is off to an outstanding start and that 2019 numbers are poised to increase".

For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.

Shares of GW Pharma closed at $152.89 yesterday.

You May Also Be Interested In

• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
• Honasa Consumer Ltd (HONASA:IN) PT Raised to INR720 at ICICI Securities